References
- Njoo MD, Westerhof W. Vitiligo. Pathogenesis and treatment. Am J Clin Dermatol 2001; 2: 167–81.
- Kemp EH, Waterman EA, Weetman AP. Autoimmune aspects of vitiligo. Autoimmunity 2001; 34: 65–77.
- Phan GQ, Atha P, Steinberg SM, White DE, Rosenberg SA. Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J Clin Oncol 2001; 19: 3477–82.
- Raanani P. Ben-Bassat I. Immune-mediated complications during interferon therapy in hematological patients. Acta Haematol 2002; 107: 133–44.
- Cohen Y, Haim S, Bartal A, Robinson E. Vitiligo asso-ciated with BCG-methanol extraction residue in malignant melanoma. Report of a case. Dermatologica 1979; 158: 8–12.
- Lamm DL. How long should adjuvant BCG be given? In: Kurth KH, Mickisch GH, Schroeder FH, eds. Renal, bladder and prostate cancer: an update. London: Parthe-non Publishing Group, 1999: 235–44.